Irbesartan/Hydrochloorthiazide STADA 300/12,5 mg, filmomhulde tabletten

Negara: Belanda

Bahasa: Belanda

Sumber: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
13-09-2023
Karakteristik produk Karakteristik produk (SPC)
13-09-2023

Bahan aktif:

HYDROCHLOORTHIAZIDE 12,5 mg/stuk ; IRBESARTAN 300 mg/stuk

Tersedia dari:

Stada Arzneimittel AG Stadastrasse 2-18 61118 BAD VILBEL (DUITSLAND)

Kode ATC:

C09DA04

INN (Nama Internasional):

HYDROCHLOORTHIAZIDE 12,5 mg/stuk ; IRBESARTAN 300 mg/stuk

Bentuk farmasi:

Filmomhulde tablet

Komposisi:

COPOVIDON (E 1208) ; CROSCARMELLOSE NATRIUM (E 468) ; HYPROMELLOSE (E 464) ; IJZEROXIDE GEEL (E 172) ; IJZEROXIDE ROOD (E 172) ; IJZEROXIDE ZWART (E 172) ; LACTOSE 1-WATER ; MACROGOL 8000 ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; SILICIUMDIOXIDE (E 551) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171), COPOVIDON ; CROSCARMELLOSE NATRIUM (E 468) ; HYPROMELLOSE (E 464) ; IJZEROXIDE GEEL (E 172) ; IJZEROXIDE ROOD (E 172) ; IJZEROXIDE ZWART (E 172) ; LACTOSE 1-WATER ; MACROGOL 8000 ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; SILICIUMDIOXIDE (E 551) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171), COPOVIDON ; CROSCARMELLOSE NATRIUM (E 468) ; HYPROMELLOSE (E 464) ; IJZEROXIDE GEEL (E 172) ; IJZEROXIDE ROOD (E 172) ; IJZEROXIDE ZWART (E 172) ; LACTOSE 1-WATER ; MACROGOL 8000 ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; SILICIUMDIOXIDE (E 551) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171),

Rute administrasi :

Oraal gebruik

Area terapi:

Irbesartan And Diuretics

Ringkasan produk:

Hulpstoffen: COPOVIDON; CROSCARMELLOSE NATRIUM (E 468); HYPROMELLOSE (E 464); IJZEROXIDE GEEL (E 172); IJZEROXIDE ROOD (E 172); IJZEROXIDE ZWART (E 172); LACTOSE 1-WATER; MACROGOL 8000; MAGNESIUMSTEARAAT (E 470b); MAÏSZETMEEL, GEPREGELATINEERD; SILICIUMDIOXIDE (E 551); TALK (E 553 B); TITAANDIOXIDE (E 171);

Tanggal Otorisasi:

1900-01-01

Selebaran informasi

                                PL Irbesartan/HCT NL1919
PACKAGE LEAFLET: INFORMATION FOR THE USER
IRBESARTAN/HYDROCHLOORTHIAZIDE STADA 150/12,5 MG, FILMOMHULDE
TABLETTEN
IRBESARTAN/HYDROCHLOORTHIAZIDE STADA 300/12,5 MG, FILMOMHULDE
TABLETTEN
IRBESARTAN/HYDROCHLOORTHIAZIDE STADA 300/25 MG, FILMOMHULDE TABLETTEN
irbesartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What  is and what it is used for
2. What you need to know before you take 
3. How to take 
4. Possible side effects
5. How to store 
6. Contents of the pack and other information
1. WHAT  IS AND WHAT IT IS USED FOR
 is a combination of two active substances, irbesartan
and hydrochlorothiazide.
Irbesartan belongs to a group of medicines known as angiotensin-II
receptor antagonists.
Angiotensin-II is a substance produced in the body that binds to
receptors in blood vessels
causing them to tighten. This results in an increase in blood
pressure. Irbesartan prevents the
binding of angiotensin-II to these receptors, causing the blood
vessels to relax and the blood
pressure to lower. Hydrochlorothiazide is one of a group of medicines
(called thiazide diuretics)
that causes increased urine output and so causes a lowering of blood
pressure.
The two active ingredients in  work together to lower
blood pressure further
than if either was given alone.
 IS USED TO TREAT HIGH BLOOD PRESSURE, when treatment
with irbesartan or
hydrochlorothiazide alone d
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                SmPC Irbesartan/HCT NL1919
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Irbesartan/Hydrochloorthiazide STADA 150/12,5 mg, filmomhulde
tabletten
Irbesartan/Hydrochloorthiazide STADA 300/12,5 mg, filmomhulde
tabletten
Irbesartan/Hydrochloorthiazide STADA 300/25 mg, filmomhulde tabletten
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
_ 150 mg/12.5 mg film-coated tablets _
Each film-coated tablet contains 150 mg of irbesartan and 12.5 mg of
hydrochlorothiazide.
_ 300 mg/12.5 mg film-coated tablets _
Each film-coated tablet contains 300 mg of irbesartan and 12.5 mg of
hydrochlorothiazide.
_ 300 mg/25 mg film-coated tablets _
Each film-coated tablet contains 300 mg of irbesartan and 25 mg of
hydrochlorothiazide.
Excipient(s) with known effect
_ 150 mg/12.5mg film-coated tablets _
Each film-coated tablet contains 34.16 mg lactose (as lactose
monohydrate).
_ 300 mg/12.5 mg and 300 mg/25 mg
film-coated tablets _
Each film-coated tablet contains 68.32 mg lactose (as lactose
monohydrate).
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
_ 150 mg/12.5 mg film-coated tablet _
Pink, oblong, biconvex film-coated tablet and approximately 13 mm in
length.
_ 300 mg/12.5 mg film-coated tablet _
Pink, oblong, biconvex film-coated tablet and approximately 16 mm in
length.
_ 300 mg/25 mg film-coated tablet _
Red, oblong, biconvex film-coated tablet and approximately 16 mm in
length.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Treatment of essential hypertension.
This fixed dose combination is indicated in adult patients whose blood
pressure is not
adequately controlled on irbesartan or hydrochlorothiazide alone (see
section 5.1).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
 can be taken once daily, with or without food.
Dose titration with the individual components (i.e. irbesartan and
hydrochlorothiazide) may be
recommended.
SmPC Irbesartan/HCT NL1
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Inggris 25-04-2018
Karakteristik produk Karakteristik produk Inggris 25-04-2018